Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
Farmers Insurance
Accenture
Healthtrust
Dow
Julphar
Teva
Novartis
Covington

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Amylin peptides
Abstract:A biologically active peptide associated with diabetes and designated herein "amylin" and processes for preparing it and assaying for it and for Type 2 diabetes are disclosed. The invention includes peptides having the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, substantially homologous sequences of amino acids, proamylin, as well as biologically active subfragments and conservative mutations. The peptide may be prepared from diabetic pancreata by solubilization of amyloid and isolation of the peptide by gel filtration and reverse phase chromotography. Amylin may also be synthesized, or it may be produced by recombinant DNA techniques using the disclosed nucleic acid sequences.
Inventor(s): Cooper; Garth J. S. (Solana Beach, CA), Willis; Antony C. (Witney, GB2)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:May 01, 1989
Application Number:07/346,624
Claims:1. An amylin peptide having thirty-seven amino acids, in which the C-terminal tyrosine of said peptide is carboxyamidated, said peptide contains an intramolecular linkage between cysteine resides at positions 2 and 7, and wherein said peptide is capable of reducing insulin-induced incorporation of glucose into glycogen in isolated rat soleus muscle.

2. The amylin peptide KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY which contains an intramolecular linkage between the cysteine residues at positions 2 and 7, and wherein the C-terminal tyrosine is carboxyamidated.

3. A process for the preparation of an amylin peptide as recited in claim 2, comprising the steps of (a) preparing solubilized amyloid by use of formic acid in conjunction with ultrasound, (b) subjecting the amyloid material from step (a) to normal phase high performance liquid chromatography gel filtration using a mobile phase comprising aqueous guanidine and sodium phosphate, and (c) subjecting the amyloid material from step (b) to high performance liquid chromatography using a mobile phase comprising triflouracetic acid and elution by acetonitrile.

4. A substantially pure amylin peptide prepared by the process of claim 3.

5. An amylin peptide as recited in claim 1 or 2 which is at least about 50% pure.

6. An amylin peptide as recited in claim 1 or 2 which is at least about 80% pure.

7. An amylin peptide as recited in claim 1 or 2 which is at least about 90% pure.

8. An amylin peptide as recited in claim 1 or 2 which is at least about 95% pure.

9. An amylin peptide as recited in claim 1 or 2 which is at least about 99% pure.

10. The amylin peptide of claim 4 wherein said amylin peptide is an amylin peptide having thirty-seven amino acids, in which the C-terminal tyrosine of said peptide is carboxyamidated. said peptide contains an intramolecular linkage between the cysteine residues at positions 2 and 7, and wherein said peptide is capable of reducing insulin-induced incorporation of glucose into glycogen in isolated rat soleus muscle.

11. The amylin peptide of claim 5 wherein said amylin peptide is an amylin peptide having thirty-seven amino acids, in which the C-terminal tyrosine of said peptide is carboxyamidated, said peptide contains an intramolecular linkage between the cysteine residues at positions 2 and 7, and wherein said peptide is capable of reducing insulin-induced incorporation of glucose into glycogen in isolated rat soleus muscle.

12. The amylin peptide of claim 6 wherein said amylin peptide is an amylin peptide having thirty-seven amino acids, in which the C-terminal tyrosine of said peptide is carboxyamidated, said peptide contains an intramolecular linkage between the cysteine residues at positions 2 and 7, and wherein said peptide is capable of reducing insulin-induced incorporation of glucose into glycogen in isolated rat soleus muscle.

13. The amylin peptide of claim 7 wherein said amylin peptide is an amylin peptide havng thirty-seven amino acids, in which the C-terminal tyrosine of said peptide is carboxyamidated, said peptide contains an intramolecular linkage between the cysteine residues at positions 2 and 7, and wherein said peptide is cabable of reducing insulin-induced incorporation of glucose into glycogen in isolated rat soleus muscle.

14. The amylin peptide of claim 8 wherein said amylin peptide is an amylin peptide having thirty-seven amino acids, in which the C-terminal tyrosine of said peptide is carboxyamidated, said peptide contains an intramolecular linkage between the cysteine residues at positions 2 and 7, and wherein said peptide is capable of reducing insulin-induced incorporation of glucose into glycogen in isolated rat soleus muscle.

15. The amylin peptide of claim 9 wherein said amylin peptide is an amylin peptide having thirty-seven amino acids, in which the C-terminal tyrosine of said peptide is carboxyamidated, said peptide contains an intramolecular linkage between the cysteine residues at positions 2 and 7, and wherein said peptide is capable of reducing insulin-induced incorporation of glucose into glycogen in isolated rat soleus muscle.

16. The amylin peptide of claim 4 wherein said amylin peptide is the amylin peptide KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY which contains an intramolecular linkage between the cysteine residues at positions 2 and 7, and wherein the C-terminal tyrosine is carboxyamidated.

17. The amylin peptide of claim 5 wherein said amylin peptide is the amylin peptide KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY which contains an intramolecular linkage between the cysteine residues at positions 2 and 7, and wherein the C-terminal tyrosine is carboxyamidated.

18. The amylin peptide of claim 6 wherein said amylin peptide is the amylin peptide KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY which contains an intramolecular linkage between the cysteine residues at positions 2 and 7, wherein the C-terminal tyrosine is carboxyamidated.

19. The amylin peptide of claim 7 wherein said amylin peptide is the amylin peptide KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY which contains an intramolecular linkage between the cysteine residues at positions 2 and 7, wherein the C-terminal tyrosine is carboxyamidated.

20. The amylin peptide of claim 8 wherein said amylin peptide is the amylin peptide KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY which contains an intramolecular linkage between the cysteine residues at positions 2 and 7, wherein the C-terminal tyrosine is carboxyamidated.

21. The amylin peptide of claim 9 wherein said amylin peptide is the amylin peptide KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY which contains an intramolecular linkage between the cysteine residues at positions 2 and 7, wherein the C-terminal tyrosine is carboxyamidated.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Healthtrust
Citi
US Army
Chinese Patent Office
Queensland Health
Johnson and Johnson
Baxter
Fish and Richardson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot